October 19 , CombiGene invites analysts and shareholders to the company’s presentation at Aktiespararna’s digital event
CEO Jan Nilsson and Karin Agerman present CombiGene at Aktiespararna’s digital event in Stockholm October 19
Don’t miss this opportunity to get a comprehensive presentation of CombiGene’s latest advances in the epilepsy project CG01 and the fantastic opportunities that this project holds.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.